InhaTarget Therapeutics is a spin-off company from the University of Brussels (ULB) - Belgium, dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, with a first focus on lung cancer. The company was established in August 2019 and brings together strong complementary expertise in drug formulation, inhalation delivery, immunology, preclinical development and clinical operations.
Follow our LinkedIn and stay up to date with our latest activities.
InhaTarget Therapeutics at the European Society for Medical Oncology European Lung Cancer Congress 2023
InhaTarget Therapeutics is featured in this article on inhalable drugs published in The Wall Street Journal